title: The role of stem-cell transplantation in the treatment of marginal zone lymphoma.
abstract: High-dose chemotherapy and autologous stem-cell transplantation (ASCT) is standard therapy in relapsed/refractory aggressive lymphoma. The optimal therapy of relapsed/refractory disseminated marginal-zone lymphoma (MZL) has not been defined. Limited data on ASCT in this setting suggests outcomes are similar to what is expected in follicular lymphoma. International guidelines suggest that ASCT should be considered in follicular lymphoma in second or subsequent remission, in particular in high-risk disease, or following disease transformation. These guidelines can be extrapolated to MZL. ASCT is not considered curative but a subset of patients achieve very long remissions. The major concern is the occurrence of secondary malignancies possibly related to total-body irradiation. Allogeneic SCT is usually considered after failure of ASCT, but can also be considered upfront in younger patients seeking curative approach. The introduction of novel/targeted therapies may change the role and timing SCT may have in the treatment algorithm of indolent lymphomas.
authors.affiliation: The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, Israel. Electronic address: ashimoni@sheba.health.gov.il.
authors.forename: Avichai
authors.initials: A
authors.lastname: Shimoni
mesh_terms: D000465:Algorithms; D064591:Allografts; D064592:Autografts; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000628:therapy*; D017410:Practice Guidelines as Topic; D033581:Stem Cell Transplantation
keywords: Marginal-zone lymphoma; Stem-cell transplantation